Last reviewed · How we verify
Retigabine
At a glance
| Generic name | Retigabine |
|---|---|
| Also known as | GKE-841, D-23129, ezogabine |
| Sponsor | Bausch Health Americas, Inc. |
| Target | Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3, Potassium voltage-gated channel subfamily KQT member 4 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | discontinued |
Approved indications
- Partial Epilepsy Treatment Adjunct
Common side effects
Key clinical trials
- Meta-Analysis of VRX-RET-E22-303 and VRX-RET-E22-304: Two Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Studies of Retigabine in Adult Epilepsy Patients With Partial-onset Seiz (N/A)
- European Survey of Patient and Prescriber Understanding of Risks Associated With Trobalt™ (N/A)
- REMS Prescriber and Pharmacist Understanding of the Risk of Urinary Retention With POTIGA™ (N/A)
- Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures (Phase 4)
- A Multicenter, Open-label, Long-term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-onset Seizures (Extension of Study VRX-RET-E22-301) (Phase 3)
- Developing Neuronal KCNQ Channel Modulators for Mood Disorders (Phase 2)
- Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study (Phase 3)
- RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (>= 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (>=12 Ye (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Retigabine CI brief — competitive landscape report
- Retigabine updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI